Christine Murray
General Counsel at CYTOKINETICS, INCORPORATED
Net worth: 1 116 $ as of 2024-04-29
Christine Murray active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CYTOKINETICS, INCORPORATED | General Counsel | 2023-03-31 | - |
Career history of Christine Murray
Former positions of Christine Murray
| Companies | Position | Start | End |
|---|---|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Director/Board Member | 2019-01-06 | 2024-03-14 |
| Independent Dir/Board Member | 2019-01-06 | 2024-03-14 | |
| ULTRAGENYX PHARMACEUTICAL INC. | General Counsel | 2018-06-30 | 2021-08-31 |
Raptor Pharmaceuticals, Inc.
 Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Corporate Officer/Principal | 2014-12-31 | 2017-01-31 |
| RAPTOR PHARMACEUTICAL CORP | General Counsel | 2015-02-28 | 2016-12-31 |
| ACHAOGEN | General Counsel | 2011-07-31 | 2015-01-01 |
Training of Christine Murray
| The University of Liverpool | Undergraduate Degree |
| Newcastle University | Graduate Degree |
Statistics
International
| United States | 7 |
| United Kingdom | 3 |
Operational
| General Counsel | 4 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| Private companies | 3 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Health Technology |
- Stock Market
- Insiders
- Christine Murray
- Experience